Global adverse.events@ipsen.com Algeria pharmacovigilance.algeria@ipsen.com Australia pharmacovigilance.australia@ipsen.com Austria pharmacovigilance.germany@ipsen.com Belgium pharmacovigilance.belgium@ipsen.com Brazil pharmacovigilance.brasil@ipsen.com Canada pharmacovigilance.canada@ipsen.com China pharmacovigilance.china@ipsen.com Hong Kong – PRC pharmacovigilance.hongkong@ipsen.com Colombia pharmacovigilance.colombia@ipsen.com Czech Republic pharmacovigilance.czech@ipsen.com Denmark pharmacovigilance.nordic@ipsen.com Finland pharmacovigilance.nordic@ipsen.com France pharmacovigilance.france@ipsen.com Germany pharmacovigilance.germany@ipsen.com Greece pharmacovigilance.greece@ipsen.com Hungary pharmacovigilance.hungary@ipsen.com Ireland pharmacovigilance.uk-ie@ipsen.com Italy pharmacovigilance.italy@ipsen.com Japan pv.japan@ipsen.com Kazakhstan pharmacovigilance.kazakhstan@ipsen.com Latvia pharmacovigilance.baltic@ipsen.com Lithuania pharmacovigilance.baltic@ipsen.com Luxembourg pharmacovigilance.belgium@ipsen.com Mexico pharmacovigilance.mexico@ipsen.com Netherlands pharmacovigilance.netherlands@ipsen.com Norway pharmacovigilance.nordic@ipsen.com Poland pharmacovigilance.poland@ipsen.com Portugal pharmacovigilance.portugal@ipsen.com Romania pharmacovigilance.romania@ipsen.com Russian Federation pharmacovigilance.russia@ipsen.com Singapore pharmacovigilance.sg@ipsen.com Slovakia pharmacovigilance.slovakia@ipsen.com South Korea pharmacovigilance.korea@ipsen.com Spain pharmacovigilance.spain@ipsen.com Sweden pharmacovigilance.nordic@ipsen.com Switzerland pharmacovigilance.germany@ipsen.com Taiwan pharmacovigilance.taiwan@ipsen.com Tunisia pharmacovigilance.tunisie@ipsen.com Ukraine pharmacovigilance.ukraine@ipsen.com United Arab Emirates pharmacovigilance.ksa@ipsen.com United Kingdom pharmacovigilance.uk-ie@ipsen.com United States of America pharmacovigilance.usa@ipsen.com Vietnam pharmacovigilance.vietnam@ipsen.com